Rafael Proxy Seeks 2.42M More Plan Shares to Enable 1.93M Options Tied to FDA Approval
RFL is trading near its 52-week low of $0.99 (9.1% above the low) on light trading volume (0.2× avg).
Summary
Rafael's definitive proxy asks shareholders to add 2,422,483 shares to the 2021 Equity Incentive Plan — the condition for 1,925,670 options granted in August 2026 to remain exercisable — alongside routine director elections, auditor ratification and say-on-pay at the January 7, 2027 meeting.
Key Events · Corporate Governance and Compliance · RFL
-
Proxy Sets January 7 Meeting
Shareholders of record on November 10, 2026 will vote on six director nominees, ratification of CohnReznick for fiscal 2027, the 2021 Plan amendment and an advisory say-on-pay vote.
-
Plan Expansion Enables 1.93M Options
Proposal 3 raises the 2021 Plan pool by 2,422,483 shares, from 4,365,795 to 6,788,278, which is required for the 1,925,670 options granted August 18, 2026 at $1.87 to be exercisable.
-
Vesting Hinges on FDA Approval
Half the options vest only on FDA approval of Trappsol Cyclo plus issuance of a priority review voucher, 25% on the 12-month and 25% on the 24-month anniversary; all are forfeited if approval is not obtained by August 12, 2027.
-
Insider Grants Concentrated
Of the August 2026 grants, Howard Jonas received 728,170 options, Joshua Fine 390,000 and David Polinsky 165,000, with 642,500 going to other employees and consultants.
Analysis · RFL · Life Sciences
The annual meeting itself is routine, but Proposal 3 is not: the August 18, 2026 option grants to management and consultants — 1,925,670 shares at $1.87 — are void unless shareholders expand the 2021 Plan by 2,422,483 shares. Those options only pay off if the FDA approves Trappsol Cyclo and issues a priority review voucher by August 12, 2027, so the vote is effectively a referendum on the NDA filed in October. Against a going-concern warning and $22.1 million of cash, the plan expansion also adds a fresh equity overhang on top of the existing 52.2 million shares outstanding.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RFL was trading at $1.08 on NYSE in the Life Sciences sector, with a market capitalization of approximately $55.8M. The 52-week trading range was $0.99 to $3.96. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.